Search clinical trials for: Raltegravir (MK-0518)

Total 2111 results

Centre de Recherches et d'Etude sur la Pathologie...

Recruiting

HIV-1 Infected Patients, Phase II Trial, Dual Combination Doravirine/Raltegravir Open Label (DORAL)

HIV Infections

France
Yale University
Bristol-Myers Squibb; Merck Sharp & Dohme LLC

Completed

Pilot Study of a Raltegravir Based NRTI Sparing Regimen

HIV Infections | Human Immunodeficiency Virus | AIDS | Acquired Immune Deficiency Syndrome

United States
Kirby Institute

Completed

Raltegravir and Atazanavir Dosing Strategy Study (SPARTA)

HIV Infection

Australia
University of Copenhagen

Completed

GLP-1 Response and Effect in Individuals With Obesity Causing Genetic Mutations

Obesity

Denmark
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)

Colorectal Neoplasms

United States, Canada
Merck Sharp & Dohme LLC

Completed

Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)

Advanced/Metastatic Solid Tumors

United States, Canada
Merck Sharp & Dohme LLC

Terminated

A Single Dose Study to Investigate the Pharmacokinetics of MK-0941 in Participants With Renal Insufficiency (MK-0941-015-02)

Type 2 Diabetes
Guy's and St Thomas' NHS Foundation Trust

Completed

Time to Protection and Adherence Requirements of Raltegravir With or Without Lamivudine in Protection From HIV Infection (R-PrEP)

Hiv

United Kingdom
Merck Sharp & Dohme LLC

Completed

The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)

Breast Cancer
Alimera Sciences
CBCC Global Research

Recruiting

Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis

Uveitis, Posterior

United States
Acceleron Pharma, Inc., a wholly-owned subsidiary...

Recruiting

Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13) (HYPERION)

Pulmonary Arterial Hypertension

United States, Belgium, France, Germany, Spain, Argentina, Australia, Austria, Colombia, Croatia, Denmark, Greece, Israel, Korea, Republic of, Netherlands, Portugal, Serbia, Taiwan, Brazil, Canada, Czechia, Italy, New Zealand, Sweden, S... and more
Acceleron Pharma, Inc., a wholly-owned subsidiary...

Active, not recruiting

A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH) (ZENITH)

Pulmonary Arterial Hypertension

France, Germany, United States, Australia, Belgium, Canada, Israel, Italy, Mexico, Netherlands, Spain, United Kingdom
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035) (VICTOR)

Chronic Heart Failure With Reduced Ejection Fraction

China, United States, Argentina, Australia, Austria, Brazil, Canada, Chile, Colombia, Czechia, Denmark, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Ireland, Israel, Italy, Korea, Republic of, Malaysia, Mexico, New Zealand, Peru and more
Afferent Pharmaceuticals, Inc.

Completed

A Study of Gefapixant (AF-219/MK-7264) in Participants With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)

Cough | Idiopathic Pulmonary Fibrosis
Merck Sharp & Dohme LLC

Completed

Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)

Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
Merck Sharp & Dohme LLC

Not yet recruiting

A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01)

Neoplasm Metastasis
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability and Pharmacokinetics of MK-0873 Following Patch Application in Healthy Participants and Psoriasis Participants (MK-0873-020)

Plaque Psoriasis
NS Pharma, Inc.
Nippon Shinyaku Co., Ltd.

Terminated

Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Thailand, Malaysia, Korea, Republic of, Italy, United Kingdom, Poland, Germany, Turkey
Merck Sharp & Dohme LLC

Active, not recruiting

Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)

Kidney Failure, Chronic | End-Stage Renal Disease | End-Stage Kidney Disease

United States, Argentina, Australia, Brazil, Bulgaria, Canada, Czechia, Germany, Greece, Italy, Portugal, Puerto Rico, Romania, Russian Federation, Sweden
Afferent Pharmaceuticals, Inc.

Completed

A Four-Week Multicenter Study Evaluating the Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Subjects With Osteoarthritis of the Knee

Osteoarthritis of the Knee

United States
University of Virginia
Merck Sharp & Dohme LLC; National Institutes of Health (NIH)

Withdrawn

Growth Hormone Secretagogue MK-0677's Effect on Lean Body Mass in Chronic Kidney Disease Stage 4/5 Subjects

Chronic Kidney Disease | Kidney Disease

United States
Dar Al Shifa Hospital

Completed

Visumax Femtolasik Versus Moria M2 Microkeratome in Myopia

Lasik in Myopia
Hillier, Sharon, PhD
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Safety and Pharmacokinetics of Two Vaginal Film Formulations Containing the Integrase Inhibitor MK-2048 (FAME103)

Pharmacokinetics | Safety

United States
Nantes University Hospital

Completed

QDISS Stud: QD Isentress as Switch Strategy in Virologically Suppressed HIV-1 Infected-Patient (QDISS)

Virus-HIV

France
Merck Sharp & Dohme LLC

Completed

A Pharmacokinetic Study to Evaluate the Effect of MAALOX on Raltegravir (MK-0518) in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-295)

HIV Infections
National Center for Global Health and Medicine,...
Ministry of Health, Labour and Welfare, Japan

Completed

Comparing Continuing Tenofovir, Emtricitabine (or Lamivudine) Plus Lopinavir and Switching to Raltegravir Plus Darunavir (SPARE)

HIV Infections

Japan
Andrew Carr
Merck Sharp & Dohme LLC

Completed

Raltegravir Use as Nonoccupational Postexposure Prophylaxis (NPEP) in Men Who Have Sex With Men (RAL-NPEP)

HIV Infections | HIV Prevention

Australia
Merck Sharp & Dohme LLC

Terminated

Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155)

rrCLL | rrMM | rrDLBCL
Merck Sharp & Dohme LLC

Not yet recruiting

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Burkitt Lymphoma | Ewing Sarcoma | Neuroblastoma | Diffuse Large B-cell Lymphoma | B-cell Acute Lymphoblastic Leukemia
Merck Sharp & Dohme LLC

Recruiting

A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)

Hepatic Impairment | Non-alcoholic Steatohepatitis

United States
VelosBio Inc.

Completed

A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002)

Gastric Cancer | Pancreatic Cancer | NSCLC | Platinum-resistant Ovarian Cancer | Triple-negative Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer | Non-squamous Non-small-cell Lung Cancer | Estrogen-receptor-positive Breast Cancer | Progesterone-receptor-positive Breast Cancer | Estrogen-receptor-negative... and other conditions

United States, Canada
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate Molnupiravir (MK-4482; MOV) in Participants With Severe Renal Impairment (MK-4482-003)

Renal Impairment

United States
Afferent Pharmaceuticals, Inc.

Completed

Effect of Gefapixant (AF-219/MK-7264) on Cough Reflex Sensitivity (MK-7264-015)

Refractory Chronic Cough

United Kingdom
Afferent Pharmaceuticals, Inc.

Completed

A Study to Assess the Efficacy of Gefapixant (MK-7264/AF-219), in Participants With Chronic Cough (MK-7264-006) (EPICC)

Chronic Cough
Merck Sharp & Dohme LLC

Completed

Study of Gefapixant (MK-7264) in Adult Japanese Participants With Unexplained or Refractory Chronic Cough (MK-7264-033)

Chronic Cough

Japan
National Cancer Institute (NCI)

Active, not recruiting

Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer

Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Advanced Malignant Solid Neoplasm | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma... and other conditions

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)

Advanced Hepatocellular Carcinoma

United States, China, Italy, Japan, Korea, Republic of, Poland, Spain, Switzerland, Taiwan
Kristine Patterson, MD
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Sex, Aging and Antiretroviral Pharmacokinetics

HIV Infections

United States
Merck Sharp & Dohme LLC

Terminated

Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062)

Neoplasm

United States, Canada, Israel
Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)

Bladder Cancer

Canada, France, Italy, Netherlands, Turkey, Brazil, Spain, United States, Finland, Puerto Rico, Singapore
Merck Sharp & Dohme LLC

Active, not recruiting

Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Investigational Agents for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)

Small Cell Lung Carcinoma

Poland, Russian Federation, United States, Australia, Austria, Canada, Hungary, Israel, Italy, Korea, Republic of, Spain, Switzerland
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

Carcinoma, Renal Cell

United States, Colombia, Canada, Australia, Finland, Japan, United Kingdom, Brazil, Chile, China, Croatia, Czechia, Denmark, France, Germany, Guatemala, Hungary, Ireland, Italy, Korea, Republic of, Malaysia, Mexico, Norway, Philippines, Polan... and more
ANRS, Emerging Infectious Diseases
Merck Sharp & Dohme LLC; Janssen-Cilag Ltd.

Completed

Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL

HIV-1 Infection

Spain, France
Kirby Institute
Merck Sharp & Dohme LLC

Completed

The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection (PINT)

HIV Infection

Australia
Groupe d'Etude sur le Risque d'Exposition des Soignants...
Merck Sharp & Dohme LLC

Completed

Safety Study of Isentress® + Truvada® in Post-exposure Treatment of HIV Infection

HIV Infections

France
Central Institute of Epidemiology, Moscow, Russia
Merck Sharp & Dohme LLC

Unknown

Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients

HIV Infections | Tuberculosis

Russian Federation
Merck Sharp & Dohme LLC

Active, not recruiting

Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)

Melanoma

United States, Australia, France, Israel, Italy, Switzerland
Peloton Therapeutics, Inc., a subsidiary of Merck...

Active, not recruiting

A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)

Kidney Cancer | Renal Cell Carcinoma | Clear Cell Renal Cell Carcinoma | ccRCC | RCC

United States
The University of Texas Health Science Center at...
Merck Sharp & Dohme LLC; VA Office of Research and Development; Centers for Disease...

Completed

The Effect of Rifapentine on Raltegravir

Healthy

United States
Imperial College London
Medical Research Council; University of Oxford; Guy's and St Thomas' NHS Foundation... and other collaborators

Completed

Research In Viral Eradication of HIV Reservoirs (RIVER)

HIV

United Kingdom

Search clinical trials for: Raltegravir (MK-0518)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ireland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations